

ASTERAND PLC

(‘Asterand’ or ‘the Company’)

Signs global agreement with Lundbeck giving access to its human tissue samples and drug discovery services

Asterand plc (LSE: ATD), (“Asterand” or the “Company”), a leading provider of human tissue and human tissue-based services to pharmaceutical and biotechnology companies engaged in drug discovery research, announces today that it has entered into a Global Framework Research Agreement with Lundbeck A/S, a leading international pharmaceutical company focused on the development of medications for central nervous system disorders. This agreement will allow scientists at Lundbeck’s global research locations to access Asterand’s XpressBANK™ of human tissue and clinical data and the PhaseZERO® drug discovery services platform to advance development of treatments for psychiatric and neurological disorders. Financial terms were not disclosed.

Martyn Coombs, CEO of Asterand commented:

“We are honoured that Lundbeck has chosen Asterand as a preferred human tissue solutions provider. As we seek avenues to create closer relationships with our key clients, this extended collaboration provides Asterand with the opportunity to assist Lundbeck in its quest to find treatments for difficult to treat diseases such as Alzheimer’s, Parkinson’s and Schizophrenia.”

For further information contact:

Asterand plc

Martyn Coombs, Chief Executive Officer

Tel: + 44 (0) 1763 211 600 /
+ 1 (313) 263-0960
As above

John Stchur, Chief Financial Officer

Buchanan Communications

Lisa Baderoon / Rebecca Skye Dietrich / Jennie Spivey

Tel: +44 (0) 20 7466 5000

Cenkos Securities plc

Stephen Keys / Alex Ayles

Tel: + 44 (0) 20 7397 8924

Daniel Stewart & Company plc

Simon Starr

Tel: +44 (0) 20 7776 6550

Notes to Editors

About Asterand plc

Asterand plc is a leading supplier of high quality human tissue and tissue-based services. Our comprehensive approach to human tissue and research services offers pharmaceutical, biotech and diagnostic companies the unique opportunity to have one Company meet all of their human biomaterial needs along the continuum of drug discovery and development. Our mission is to accelerate target discovery and compound validation and enable pharmaceutical and biotechnology companies to take safer and more effective drugs into the clinic.

About Lundbeck A/S

H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improve the quality of life for people suffering from central nervous system (CNS) disorders. For this purpose Lundbeck is engaged in the research and development, production, marketing and sale of pharmaceuticals across the world, targeted at disorders like depression and anxiety, schizophrenia, insomnia, Huntington's, Alzheimer's and Parkinson's diseases.

Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark, and employs today over 5,500 people worldwide. Lundbeck is one of the worlds leading pharmaceutical companies working with CNS disorders. In 2008, the company's revenue was DKK 11.3 billion (approximately EUR 1.5 billion or USD 2.2 billion). For more information, please visit www.lundbeck.com.